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Abstract : The aim of this study was to determine the expression of human 
epidermal growth factor receptor type 2 （HER2）, epidermal growth factor 
receptor （EGFR）, peroxisome proliferator-activated receptor γ （PPARγ）, 
CD44 and androgen receptor （AR） in adenoid cystic carcinomas （ACC）, 
carcinoma ex pleomorphic adenomas （CXPA） and mucoepidermoid carcinomas
（MEC）of the salivary glands, to investigate their molecular difference and 
to estimate the availability of molecular-targeted and hormonal therapy in 
salivary-gland tumors.  Forthy patients with a salivary gland tumor, diagnosed 
and treated at our hospital, were studied.  On the basis of histopathology, 10, 
19 and 11 patients were identied with ACC, CXPA and MEC, respectively.  
The associations between histological types were evaluated by the chi-square 
test.  Differences were considered statistically signicant at P＜ 0.05.  HER2-
positive expression was observed in 10% of ACC, 84% of CXPA and 18% 
of MEC.  EGFR-positive expression was observed in 40% of ACC, 68% of 
CXPA and 91% of MEC.  CD44-positive expression was observed in 40% 
of ACC, 47% of CXPA and 91% of MEC.  PPARγ-positive expression was 
observed in 10% of ACC, 53% of CXPA and 18% of MEC.  AR-positive 
expression was observed in 20% of ACC, 32% of CXPA and 9% of MEC.  
Compared with other histological types, CXPA demonstrated signicant HER2 
and PPARγ staining and MEC demonstrated significant EGFR and CD44 
staining.  The differences in expression of markers between histological types 
in our study suggests the possibility that HER2- and PPARγ-targeted therapy 
may be effective in CXPA, and that EGFR-target therapy may be effective in 
MEC of the salivary glands.
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Introduction
　Tumors of the salivary glands account for 5% of all neoplasms of the head and neck 1）. 
These tumors arise primarily in the parotid gland, occasionally in the submandibular and 
intraoral glands, and rarely in the sublingual glands 1）.  Approximately 25% of tumors in the 
parotid gland and 50% of tumors in the other salivary glands are malignant 2）.  There are 
various histological types of the malignant neoplasm of the salivary glands.  These include 
adenoid cystic carcinomas （ACC）, carcinoma ex pleomorphic adenomas （CXPA） and 
mucoepidermoid carcinomas （MEC）, which account for approximately 5% of salivary gland 
neoplasms.  Other histological types are uncommon.
　Surgical resection is the primary treatment of neoplasms of the salivary gland at initial 
diagnosis.  Radiation therapy is usually administered to patients with advanced disease, inad-
equate margins and those who exhibit poor prognostic features such as perineural invasion 
or anaplastic histology 3）.  Chemotherapy has generally been reserved for patients with incur-
able salivary neoplasms.  The typical treatment-response rate of patients with salivary gland 
tumors is 15 - 30%, and patients usually have a short survival period.  The most active 
single agents include cisplatin, cyclophosphamide, doxorubicin and 5-uorouracil.  There is a 
denite need for additional therapeutic strategies to improve the survival and quality of life 
for these patients.   
　Molecular-targeted therapy and hormonal therapy are impacting positively on the daily 
practice of clinical oncology and are potential treatment strategies for this patient group. 
Tumor biomarker overexpression also has therapeutic implications.  Several studies have 
demonstrated the in vitro and in vivo efcacy of some antibodies on human cancers.  Those 
that are efficacious include human epidermal growth factor receptor type 2 （HER2） in 
breast cancer 4）, epidermal growth factor receptor （EGFR） in colon cancer 5）, CD44 in head 
and neck squamous cell carcinoma cells 6）, peroxisome proliferator activated receptor γ 
（PPARγ） in bladder tumor cells 7）, and androgen receptor （AR） in prostate cancer 8）.
　The purpose of the present study was to determine the expression of HER2, EGFR, 
PPARγ, CD44 and AR in ACC, CXPA and MEC of the salivary glands, to investigate the 
difference in their expression and to estimate the efcacy of molecular-targeted and hor-
monal therapy in salivary gland tumors.
Materials and Methods
Patients and samples
　This study included 40 patients diagnosed and treated for a primary malignant salivary 
gland tumor at our hospital since 1990.  All patients underwent surgical resection of the 
tumor.  On the basis of histopathology, 10, 19 and 11 patients were identied with ACC, 
CXPA and MEC, respectively.
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Immunohistological staining
　For the immunohistochemical staining for HER2 （clone CB11 ; Ventana, Tucson, AZ, 
USA, diluted 1 : 100）, EGFR （clone 3C6 ; Ventana, Tucson, USA, diluted 1 : 100）, CD44 
（clone G44-26 ; BD Bioscience, San Jose, California, USA, diluted 1 : 100）, PPARγ （clone 
E-8 ; Santa Cruz Biotechnology, Santa Cruz, CA, USA, diluted 1 : 50） and AR （clone 
AR27 ; invitrogen, Flynn RD, Camarillo, CA, USA, diluted 1 : 200）.  5-μm-thick sections 
from representative blocks of each tumor were used.
　The labeled streptavidin-biotin-peroxidase technique was used.  Sections were deparaf-
finized in xylene and dehydrated in descending grades （100-50%） of ethanol.  For 
HER2, they were incubated with 1% hydrogen peroxide in ethanol for 30  minutes to 
quench endogenous peroxidase activity.  For EGFR, CD44, PPARγ and AR, sections 
were incubated with Tris-EDTA buffer （pH 9.0） for 30 minutes.  In each case, nonspecic 
immunoreactivity was blocked by incubation with normal donkey serum for 30 min.  The 
sections were then incubated with primary antibody for 30 minutes.  After washing with 
phosphate-buffered saline （PBS） three  times, each for 5 min, the sections were incubated for 
60 min with the multilink biotinylated anti-immunoglobulin.  They were then washed with 
PBS three  times, each for 5 min, before and after being treated with streptavidin-peroxidase 
reagent for 30 min.  The reactions were visualized with diaminobenzidine （Dako） as a 
chromogen.  All steps were followed by adequate washes in PBS.  Finally, sections were 
counterstained with hematoxylin, dehydrated and mounted.
Scoring
　The intensity of the immunoreactions （negative, positive） was assessed for each case.  For 
HER2, EGFR and CD44, expression was considered positive only if distinct membranous 
immunoreactivity was present.  The tumors in which immunoreactive tumor cells constituted 
＞10% of the tumor were graded as positive 9, 10）.  PPARγ expression was considered 
positive only if distinct cytoplasmic immunoreactivity was present.  The tumors in which 
immunoreactive tumor cells constituted ＞20% of the tumor were graded as positive 11）.  AR 
expression was considered positive only if distinct nuclear immunoreactivity was present. 
The tumors in which immunoreactive tumor cells constituted ＞10% of the tumor were 
graded as positive 12）.
　All slides were evaluated independently by at least two investigators.
Analysis
　The associations between histological types were evaluated by the chi-square test.  Differ-
ences were considered statistically signicant at P＜ 0.05.
Results 
　HER2-positive expression was observed in 10% （1/10） of ACC, 84% （16/19） of CXPA 
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and 18% （2/11） of MEC （Figs. 1, 2, 3）.  There was a significant difference in HER2 
expression between each histological type （P＜ 0.05） （Table 1）.  Moreover signicant differ-
ences in HER2 expression between ACC and CXPA, and between CXPA and MEC were 
observed （P＜ 0.05） （Fig. 4）.
　EGFR-positive expression was observed in 40% （4/10） of ACC, 68% （13/19） of CXPA 
and 91 （10/11） of MEC （Figs 1, 2, 3）.  A significant difference in EGFR expression 
between each histological type was observed （P＜ 0.05） （Table 1）.  A signicant difference 
in EGFR expression between ACC and MEC was also observed （P＜ 0.05） （Fig. 4）.
　CD44-positive expression was observed in 40% （4/10） of ACC, 47% （9/19） of CXPA and 
91% （10/11） of MEC （Figs. 1, 2, 3）.  A signicant difference in CD44 expression between 
each histological type was observed （P＜ 0.05）（Table 1）.  CD44 expression also differed 
between ACC and MEC, and between CXPA and MEC （P＜ 0.05） （Fig. 5）.
　PPARγ-positive expression was observed in 10% （1/10） of ACC, 53% （10/19） of CXPA 
and 18% （2/11） of MEC （Figs. 1, 2, 3）.  Significant differences in PPARγ expression 
Fig. 1.  Immunohistochemical expression of ACC
A : Membrane staining for HER2 was not expressed in ACC.
B : Membrane staining for EGFR was not expressed in ACC.
C : Membrane staining for CD44 was not expressed in ACC.
D : Cytoplasmic staining for PPARγ was not expressed in ACC.
E : Nuclei staining for AR was not expressed in ACC.
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between each histological type （P＜ 0.05） （Table 1）, and between ACC and CXPA were 
observed （P＜ 0.05） （Fig. 5）.
　AR-positive expression was observed in 20% （2/10） of ACC, 32% （6/19） of CXPA and 
9% （1/11） of MEC （Figs. 1, 2, 3）.  No signicant differences between each histological type 
were observed （Fig. 6, Table 1）.
Discussion
　Additional strategies are required to improve the survival and quality of life of patients 
with salivary gland tumors.  In several other tumors, molecular targeted therapy with 
antibodies or antagonists and hormonal therapy are promising therapeutic strategies.  Some 
reports indicate that the appearance rates of these markers are reected in the therapeutic 
gain in vitro and in vivo.
　In breast cancer patients, HER2-overexpressing tumors are responsive to trastuzumab 
both as a single agent and in combination with other chemotherapeutic agents 4）.  Matsui et 
Fig. 2.  Immunohistochemical expression of CXPA
A : Membrane staining for HER2 was expressed in CXPA.
B : Membrane staining for EGFR was expressed in CXPA.
C : Membrane staining for CD44 was not expressed in CXPA.
D : Cytoplasmic staining for PPARγ was expressed in CXPA.
E : Nuclei staining for AR was not expressed in CXPA.
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al 13） used four human gastric cancer cell lines with various expression levels of the HER2 
protein to study the association between the expression of HER2 protein and sensitivity 
to trastuzumab.  They concluded that trastuzumab suppressed the growth of human gastric 
cancer with HER2 overexpression in vitro and in vivo and improved survival of mice with 
peritoneal dissemination and gastric cancer ascites.  In the present study, expression of 
Fig. 3.  Immunohistochemical expression of MEC
A : Membrane staining for HER2 was not expressed in MEC.
B : Membrane staining for EGFR was expressed in MEC.
C : Membrane staining for CD44 was expressed in MEC.
D : Cytoplasmic staining for PPARγ was not expressed in MEC.
E : Nuclei staining for AR was not expressed in MEC.
Table 1.   Immunohistochemical expression of HER2, EGFR, CD44, PPARγ, AR and the differ-
ence between these expressions in each histological type
HER2 EGFR CD 44 PPARγ AR
n（%） P n （%） P n （%） P n （%） P n （%） P
ACC  1/10 （10）  4/10 （40）  4/10 （40）  1/10 （10）  2/10 （20）
CXPA 16/19 （84） 13/19 （68）  9/19 （47） 10/19 （53）  6/19 （32）
MEC  2/11 （18） ＊ 10/11 （91） ＊ 10/11 （91） ＊  2/11 （18） ＊  1/11 （ 9） 0.356
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Fig. 4.   HER2 expression : A significant difference between each histological 
type （P＜ 0.05） was observed, and signicant differences between ACC 
and CXPA and between CXPA and MEC were observed （＊P＜ 0.05）.
        EGFR expression : There was a signicant difference between ACC and 
MEC （＊P＜ 0.05）.
Fig. 5.   CD44 expression : A significant difference between each histological type 
（P＜ 0.05） was observed, and significant differences between ACC and 
MEC and between CXPA and MEC （＊P＜ 0.05） were observed.
        PPARγ: Significant differences between each histological type （P＜0.05） 
and between ACC and CXPA（＊P＜ 0.05） were observed.
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HER2 was higher than the expression of other markers in CXPA suggesting that the HER2 
receptor should be specically targeted in the treatment of patients with CXPA.
　A monoclonal antibody against EGFR （Cetuximab） has demonstrated clinical efficacy 
when used alone or in combination with other chemotherapeutic agents in patients harbor-
ing EGFR-positive tumors, including chemotherapy-refractory head and neck, and colorectal, 
cancer 14）.  In addition, Bellone et al 15） reported that EGFR is highly expressed in primary 
and recurrent cervical tumors, and cetuximab appears to be a novel and attractive thera-
peutic strategy in patients harboring chemotherapy-resistant, recurrent or metastatic cervical 
cancers.  In the present study, EGFR expression in MEC was higher than expression of 
other receptors.  This suggests that specically targeting this receptor would be effective in 
the treatment of patients with MEC.
　CD44 is expressed in several tumor types.  It is involved in several processes including 
tumor proliferation, adhesion and invasion, and its role in mediating tumor progression in 
a variety of solid tumors including head and neck squamous cell carcinoma （HNSCC） has 
been studied 16）.  Wang et al 6） reported that CD44 contributes to HNSCC progression behav-
iors in vitro including tumor cell migration, proliferation and cisplatin response.  Marangoni 
et al 18） reported that CD44-positive breast cancer cells inhibited tumor growth and tumor 
recurrence following chemotherapy.  They demonstrated that CD44-positive cells play a key 
role in chemotherapy-resistant breast cancer recurrences, suggesting an innovative strategy 
to improve breast cancer treatment.  In the present study, CD44 expression in MEC was 
higher than the expression of other receptors.  Cisplatin is often used to treat patients with 
MEC.  Thus, the expression of CD44 in MEC suggested that specically targeting this recep-
tor will be effective in the treatment of patients with MEC.
　PPARγ is a member of a nuclear receptor family with diverse biological functions 
including mediation of adipocyte differentiation, regulation of monocyte–macrophage anti-
Fig. 6.   AR expression: No significant difference between 
each histological type was observed.
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inammatory activity and inhibition of cancer cell growth in vitro and in vivo 19）.  PPARγ 
is upregulated in malignant tissues, and PPARγ ligands induce terminal differentiation in 
human breast, colon and lung cancer cells, and inhibit the growth of human breast, prostate, 
gastric and lung cancer cells20, 21）.  Chang et al 21） demonstrated that two distinct PPARγ 
ligands induce differentiation and apoptosis in nonsmall-cell lung cancer in vitro.  Moreover, 
Inoue et al 22） found that the PPARγ agonist thiazolidinedione compounds inhibit the growth 
of renal cell carcinoma.  In the present study, PPARγ expression in CXPA was higher than 
the expression of other receptors suggesting the possibility of specically targeting this recep-
tor in the treatment of patients with CXPA.
　Androgens are required for the development and maintenance of normal prostate tissue 
and are also associated with carcinogenesis, tumor growth and progression in human prostate 
cancer （PCa）23）.  Barnes et al 8） demonstrated that patients with prostate carcinoma, which 
has a high frequency of AR expression, are successfully managed by anti-androgen hormonal 
treatment.  In breast cancer, Agrawal et al 24） found that the therapeutic efcacy of adjuvant 
hormone therapy was higher in AR-positive patients than in AR-negative patients.  The 
prognosis for AR-positive patients who underwent adjuvant hormone therapy was better 
than for those AR-positive patients who did not receive hormone therapy after primary 
radical surgery for breast cancer.  In the present study, AR-expression levels were low in all 
three histological types ; therefore, the efcacy of AR-targeted therapy for these tumors is 
yet to be established.
　Recent studies have reported that the markers evaluated in our study are associated with 
carcinogenesis and tumor proliferation in salivary gland tumors, and the efcacy of targeted 
therapy for salivary gland tumors has been suggested 9, 11, 25, 26）.  Haddad et al 25） reported the 
results of a phase II trial of trastuzumab in a cohort of patients with salivary gland tumors 
overexpressing HER2.  One of the three patients with MEC had a partial response, which 
is still ongoing at 45 months.  Locati et al 26） reported the results of a phase II trial using 
cetuximab in a cohort of patients with recurrent and/or metastatic salivary gland carcinomas 
（RMSGCs）.  EGFR overexpression was not statistically correlated with clinical benet, but 
high EGFR expression was correlated with a prolonged disease stabilization in half of the 
cases.  Shang et al 9） reported the results of HER2 and EGFR expression in 46 MEC and 
demonstrated that the frequency of HER2 overexpression in MEC was low, suggesting a 
limited role for HER2 in the targeted treatment of MEC.  The high frequency of EGFT 
expression in MEC gave good reason to use EGFR-targeted agents for the treatment of 
these patients.  The results of the present study and of others examining HER2 and EGFR 
expression consistently demonstrate high efcacy of EGFR and low efcacy of HER2 in 
MEC.
　Franchi et al27） examined the expression of CD44 in parotid-gland tumors.  They found 
that the malignant area of CXPA exhibited a markedly decreased CD44 expression, suggest-
ing a loss of CD44 expression associated with CXPA onset.  Consistent with the ndings of 
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Franchi et al, expression of CD44 in CXPA was low in the present study ; therefore CD44 
expression appears to correlate well with CXPA carcinogenesis.
　The present study is the rst to evaluate PPARγ expression in ACC, CXPA and MEC. 
Mukunyadzi et al 11） reported expression levels of PPARγ in 15 salivary duct carcinomas 
（SDC）.  They found no correlation between PPARγ expression and tumor stage, recurrence 
or survival, but that PPARγ is a potential target site for therapeutic manipulation.
　Sugut et al 28） reported the expression levels of AR in four acinic cell carcinomas, seven 
adenocarcinomas not otherwise specified （NOS）, 13 ACC, two CXPA, seven MEC and 
three SDC.  They found that AR was expressed in three of four SDCs, two of seven 
adenocarcinomas NOS and one of two CXPA, but no immunoreactivity was observed in 
13 ACC, seven MEC, or four acinic-cell carcinomas.  Although there were only two CXPA 
in the present series, the results of our report were consistent with previous reports and 
suggest that the expression of AR in high-grade salivary gland tumors may be used in the 
clinical management of these neoplasms.  However, Fan et al 29） examined the expression of 
AR in 13 SDC and observed strong immunostaining for AR in all cases.  They suggested 
that antiandrogen therapy used in the treatment of prostatic carcinomas may also be bene-
cial in patients with SDC.
　Previous reports have suggested the potential effectiveness of HER2-targeted therapy in 
patients with CXPA and of EGFR-targeted therapy in patients with MEC.  Furthermore, 
the effectiveness of PPARγ in CXPA and CD44 in MEC has been speculated.  By examin-
ing the expression of these markers it is possible to select those patients who would best 
respond to targeted therapies, and to identify markers associated with effective therapy. 
Concurrent therapy using combined targeted therapies and improved treatment regimens 
would result in the effective treatment of patients with salivary gland tumors.
　In summary, we investigated the expression of HER2, EGFR, CD44, PPARγ and AR in 
salivary gland tumors.  Differences in the expression of markers between the various histo-
logical types indicate the efcacy of targeted therapy of salivary gland tumors.
References
1） Heikinheimo KA, Laine MA, Ritvos OV, Voutilainen RJ, Hogan BL and Leivo IV : Bone morphogenetic pro-
tein-6 is a marker of serous acinar cell differentiation in normal and neoplastic human salivary gland. Cancer 
Res 59：5815-5821 （1999）
2） O’Brien CJ, Soong SJ, Herrera GA, Urist MM and Maddox WA : Malignant salivary tumors-analysis of prog-
nostic factors and survival. Head Neck Surg 9：82-92 （1986）
3） Spiro RH : Management of tumors of the salivary glands. Oncology （Williston Park） 12：671-680 （1998）
4） Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiremann W, Wolter J, 
Pegram M, Baselga J and Norton L : Use of chemotherapy plus a monoclonal antibody against HER2 for 
metastatic breast cancer that overexpresses HER2. N Engl J Med 344：783-792 （2001）
5） Saltz LB, Meropol NJ, Loehrer PJSr, Needle MN, Kopit J and Mayer RJ : Phase II trial of cetuximab in 
patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22：
1201-1208 （2004）
181Immunohistochemical Analysis Focusing on the Possibility of Specialized Molecular
6） Wang SJ, Wong G, de Heer Am, Xia W and Bourguignon LY : CD44 variant isoforms in head and neck 
squamous cell carcinoma progression. Laryngoscope 119：1518-1530 （2009）
7） Yoshimura R, Matsuyama M, Segawa Y, Hase T, Mitsuhashi M, Tsuchida K, Wada S, Kawahito Y, Sano H 
and Nakatani T : Expression of peroxisome proliferator-activated receptors （PPARs） in human urinary bladder 
carcinoma and growth inhibition by its agonists. Int J Cancer 104：597-602 （2003）
8） Barnes L, Rao U, Contis L, Krause J, Schwartz A and Scalamogna P : Salivary duct carcinoma. Part II : 
immunohistochemical evaluation of 13 cases for estrogen and progesterone receptors, cathepsin D and c-erbB-2 
protein. Oral Surg Oral Med Oral Pathol 78：74-80 （1994）
9） Shang J, Shui Y, Sheng L, Wang K, Hu Q and Wei Q : Epidermal growth factor receptor and human epi-
dermal growth receptor 2 expression in parotid mucoepidermoid carcinoma : possible implications for targeted 
therapy. Oncol Rep 19：435-440 （2008）
10） Hong SP, Wen J, Bang S, Park S and Song SY : CD44-positive cells are responsible for gemcitabine resistance 
in pancreatic cancer cells. Int J Cancer 125：2323-2331 （2009）
11） Mukunyadzi P, Ai L, Portilla D, Barnes EL and Fan CY : Expression of peroxisome proliferator-activated recep-
tor gamma in salivary duct carcinoma : immunohistochemical analysis of 15 cases. Mod Pathol 16：1218-1223 
（2003）
12） Lee P, Rosen DG, Zhu C, Silva EG and Liu J : Expression of progesterone receptor is a favorable prognostic 
marker in ovarian cancer. Gynecol Oncol 96：671-677 （2005）
13） Matsui Y, Inomata M, Tojigamori M, Sonoda K, Shiraishi N and Kitano S : Suppression of tumor growth in 
human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model. Int J Oncol 
27：681-685 （2005）
14） Baselga J, Norton L, Masui H, Pandiella A, Coplan K, Miller WH Jr and Mendelsohn J : Antitumor effects of 
doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer 
Inst 85：1327-1333 （1993）
15） Bellone S, Frera G, Landol G, Romani C, Bandiera E, Tognon G, Roman JJ, Burnett AF, Pecorelli S and 
Santin AD : Overexpression of epidermal growth factor type-1 receptor （EGFR-R1） in cervical cancer : implica-
tions for Cetuximab-mediated therapy in recurrent/metastatic disease. Gynecol Oncol 106：513-520 （2007）
16） Turley E, Noble P and Bourguignon L : Signaling properties of hyaluronan receptors. J Biol Chem 277：4589-
4592 （2002）
17） Steven J, Gabriel W, Anne-Martine H, Weiliang X and Lilly Y : CD44 variant isoforms in head and neck 
squamous cell carcinoma progression. Laryngoscope 119：1518-1530 （2009）
18） Marangoni E, Lecomte N, Durand L, Pinieux G, Decaudin D, Chomienne C, Smadja-joffe F and Poupon M : 
CD44 targeting reduces tumor growth and prevents post-chemotherapy relapse of human breast cancers xeno-
grafts. Br J Cancer 100：918-922 （2009）
19） Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S, Miyoshi I and Koeffer HP : Ligand for 
peroxisome proliferator-activated receptor （Troglitazone） has potent antitumor effect against human prostate 
cancer both in vitro and in vivo. Cancer Res 58：3344-3352 （1998）
20） Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, Fletcher C, Singer S and Spiegelman BM : 
Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1：465-470 （1998）
21） Chang TH and Szabo E : Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid recep-
tor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Cancer Res 
60：1129-1138 （2000）
22） Inoue K, Kawahito Y, Tsubouchi Y, Khono M, Yoshimura R, Yoshizawa T and Sano H : Expression of peroxi-
some proliferator-activated receptor in renal cell carcinoma and growth inhibition by its agonists. Biochem 
Biophys Res Commun 287：727-732 （2001）
23） Debes JD and Tindall DJ : The role of androgens and the androgen receptor in prostate cancer. Cancer Lett 
187：1-7 （2002）
24） Agrawal1 AK, Jeleñ M, Grzebieniak1 Z, Zukrowski P, Rudnicki1 J and Nienartowicz E : Androgen receptors as 
Tomoaki MORI, et al182
a prognostic and predictive factor in breast cancer. Folia Histochem Cytobiol 46：269-276 （2008）
25） Haddad R, Colevas AD, Krane JF, Cooper D, Glisson B, Amerin PC, Weeks L, Costello R and Posner M : 
Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol 39：
724-727 （2003）
26） Locati L, Bossi P, Potepan P, Crippa F, Mariani L, Casieri P, Orsenigo M, Losa M, Bergamini C, Liberatoscioli 
C, Quattrone P, Calderone R, Rinaldi G, Pilotti S and Licitra L : Cetuximab in recurrent and/or metastatic 
salivary gland carcinomas : a phase II study. Oral Oncol 45：574-578 （2009）
27） Franchi A, Moroni M, Paglierani M and Santucci M : Expression of CD44 standard and variant isoforms in 
parotid gland and parotid gland tumors. J Oral Pathol Med 30：564-568 （2001）
28） Sugut D, Bien S, Ziolkowska M and Sporny S : Immunohistochemical expression of androgen receptor in 
salivary gland cancers. Pol J Pathol 59：205-210 （2008）
29） Fan CY, Wang J and Barnes EL : Expression of androgen receptor and prostatic specic markers in salivary 
duct carcinoma ; an immunohistochemical analysis of 13 cases and review of the literature. Am J Surg Pathol 
24：579-586 （2000）
［Received May 25, 2010 : Accepted June 15 2010］ 
